Human CCL4/MIP-1 beta Quantikine ELISA Kit
| Name | Human CCL4/MIP-1 beta Quantikine ELISA Kit |
|---|---|
| Supplier | R&D Systems |
| Catalog | DMB00 |
| Category | ELISA Kit |
| Prices | $479.00, $2,290.00, $15,560.00 |
| Sizes | 1 kit, 1 pack (6 Plates), 1 pack (50 Plates) |
| Assay Type | Solid Phase Sandwich ELISA |
| Sample Type | Cell Culture Supernates (10 uL), Serum (150 uL), EDTA Plasma (150 uL), Heparin Plasma (150 uL), Citrate Plasma (150 uL) |
| Sensitivity | 11 pg/mL |
| Range | 15.6 - 1,000 pg/mL (Cell Culture Supernates), 31.2 - 2,000 pg/mL (Serum, EDTA Plasma, Heparin Plasma, Citrate Plasma) |
| Format | 96-well strip plate |
| Applications | ELISA |
| Species Reactivities | Human |
| Description | The Quantikine Human MIP-1 beta Immunoassay is a 3.0 or 4.5 hour solid phase ELISA designed to measure MIP-1 beta in cell culture supernates, serum, and plasma |
| Gene | CCL4 |
| Supplier Page | Shop |
Product images
Product References
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic - Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic
Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA. J Immunol. 2016 Sep 15;197(6):2522-31.
Stability of cytokines, chemokines and soluble activation markers in unprocessed - Stability of cytokines, chemokines and soluble activation markers in unprocessed
Aziz N, Detels R, Quint JJ, Li Q, Gjertson D, Butch AW. Cytokine. 2016 Aug;84:17-24.
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 - The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145
Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V. Leukemia. 2015 Sep;29(9):1811-22.
Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the - Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the
Sadeghi M, Lahdou I, Oweira H, Daniel V, Terness P, Schmidt J, Weiss KH, Longerich T, Schemmer P, Opelz G, Mehrabi A. Br J Cancer. 2015 Sep 1;113(5):756-62.
Pleurocidin, a novel antimicrobial peptide, induces human mast cell activation - Pleurocidin, a novel antimicrobial peptide, induces human mast cell activation
Pundir P, Catalli A, Leggiadro C, Douglas SE, Kulka M. Mucosal Immunol. 2014 Jan;7(1):177-87.
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic - The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. Blood. 2012 Feb 2;119(5):1182-9.
Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to - Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to
Johnson TR, McLellan JS, Graham BS. J Virol. 2012 Feb;86(3):1339-47.
Regulation of inflammatory chemokine receptors on blood T cells associated to the - Regulation of inflammatory chemokine receptors on blood T cells associated to the
de-Oliveira-Pinto LM, Marinho CF, Povoa TF, de Azeredo EL, de Souza LA, Barbosa LD, Motta-Castro AR, Alves AM, Avila CA, de Souza LJ, da Cunha RV, Damasco PV, Paes MV, Kubelka CF. PLoS One. 2012;7(7):e38527.
CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic - CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic
Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. Blood. 2011 Feb 3;117(5):1662-9.
Lenalidomide as initial therapy of elderly patients with chronic lymphocytic - Lenalidomide as initial therapy of elderly patients with chronic lymphocytic
Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O'Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Blood. 2011 Sep 29;118(13):3489-98.